Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:ATCCode |
L01XX52
|
| gptkbp:CASNumber |
923564-51-6
|
| gptkbp:clinicalTrialPhase |
Phase II
|
| gptkbp:developedBy |
gptkb:AbbVie
gptkb:Genentech |
| gptkbp:firstDescribed |
2008
|
| gptkbp:hasMolecularFormula |
C47H55ClN6O10S
|
| gptkbp:hasPatent |
US20080275142A1
|
| gptkbp:hasSMILES |
CC1=C(C=C(C=C1)N2CCN(CC2)C(=O)COC3=CC=CC=C3)C4=CC=C(C=C4)C(=O)NCC5=CC=CC=C5
|
| https://www.w3.org/2000/01/rdf-schema#label |
Navitoclax
|
| gptkbp:legalStatus |
investigational
|
| gptkbp:mechanismOfAction |
Bcl-xL inhibitor
Bcl-2 inhibitor |
| gptkbp:molecularWeight |
974.5 g/mol
|
| gptkbp:PubChem_CID |
gptkb:DB11707
11522607 CHEMBL452195 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
neutropenia thrombocytopenia |
| gptkbp:synonym |
ABT-263
|
| gptkbp:target |
gptkb:BCL2
gptkb:BCL2L1 gptkb:BCL2L2 |
| gptkbp:UNII |
K1DI23H2PW
|
| gptkbp:usedFor |
gptkb:cancer
chronic lymphocytic leukemia solid tumors (investigational) |
| gptkbp:bfsParent |
gptkb:Bcl-xL
|
| gptkbp:bfsLayer |
7
|